Senseonics Holdings, Inc. (SENS)

NYSEAMERICAN: SENS · IEX Real-Time Price · USD
0.531
-0.032 (-5.77%)
Mar 28, 2024, 4:00 PM EDT - Market closed

Company Description

Senseonics Holdings, Inc., a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally.

The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.

It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners.

Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.

Senseonics Holdings, Inc.
Senseonics Holdings logo
Country United States
Founded 1996
Industry Medical Devices
Sector Healthcare
Employees 132
CEO Dr. Timothy T. Goodnow Ph.D.

Contact Details

Address:
20451 Seneca Meadows Parkway
Germantown, Maryland 20876
United States
Phone (301) 515-7260
Website senseonics.com

Stock Details

Ticker Symbol SENS
Exchange NYSEAMERICAN
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001616543
CUSIP Number 81727U105
ISIN Number US81727U1051
Employer ID 47-1210911
SIC Code 3823

Key Executives

Name Position
Dr. Timothy T. Goodnow Ph.D. President, Chief Executive Officer and Director
Dr. Mukul Jain Chief Operating Officer
Kenneth L. Horton General Counsel and Corporate Development Advisor
Dr. Francine Ratner Kaufman M.D. Chief Medical Officer and Director
Frederick T. Sullivan Chief Financial Officer, Secretary and Treasurer

Latest SEC Filings

Date Type Title
Mar 25, 2024 8-K Current Report
Mar 1, 2024 10-K Annual Report
Feb 29, 2024 8-K Current Report
Feb 13, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Jan 4, 2024 8-K Current Report
Nov 9, 2023 10-Q Quarterly Report
Nov 9, 2023 8-K Current Report
Sep 12, 2023 EFFECT Notice of Effectiveness
Sep 11, 2023 S-3/A [Amend] Registration statement under Securities Act of 1933
Sep 11, 2023 8-K Current Report